Helsinn has entered into an agreement to acquire worldwide rights to Actelion Pharmaceuticals’ Valchlor®/Ledaga®, (mechlorethamine/chlormethine) an alkylating agent for the topical treatment of mycosis fungoides-type cutaneous T-cell lymphoma (MF-CTCL).    Valchlor® is the first and only FDA-approved topical formulation of mechlorethamine. It was launched in the U.S. at the end of 2013 and sales have grown from $11 million in 2014 to $35 million globally in 2017. In the U.S., approximate...